Table 2.

In vitro susceptibility testing of antifungal agents on Candida pseudoaaseri VK065094^T, C. aaseri CBS 1913^T, and C. aaseri CBS 2226^a

Antifungal agent and strain	MIC (μg/ml)
	CLSI (48 h)	Etest (48 h)	Vitek 2	Micronaut
Amphotericin B
VK065094T	0.25–0.5	0.25	≤0.25–0.5	0.25–0.5
CBS 1913T	0.063–0.125	0.032	≤0.25	0.125–0.25
CBS 2226	0.031–0.063	0.064	≤0.25	0.125–0.25
Flucytosine
VK065094T	≥16	≥32	≥64	≥64
CBS 1913T	≤0.031	0.016	≤1	≤0.063
CBS 2226	≤0.031	0.016	≤1	≤0.063
Ketoconazole
VK065094T	NT	0.064	NT	0.031–0.125
CBS 1913T	NT	0.008	NT	0.016–0.031
CBS 2226	NT	0.008	NT	0.016–0.031
Fluconazole
VK065094T	0.25–0.5	0.5	≤1	0.25–0.5
CBS 1913T	0.25	0.25	≤1	0.25
CBS 2226	0.125	0.25	≤1	0.25
Itraconazole
VK065094T	0.063–0.125	0.5	NT	0.125–0.5
CBS 1913T	0.031–0.063	0.032	NT	≤0.031–0.063
CBS 2226	0.016	0.032	NT	≤0.031–0.063
Voriconazole
VK065094T	0.031–0.063	0.016	≤0.12	0.016–0.063
CBS 1913T	0.031	0.008	≤0.12	≤0.016
CBS 2226	≤0.008	0.008	≤0.12	≤0.016
Posaconazole
VK065094T	0.063–0.125	0.064	NT	0.063
CBS 1913T	0.016–0.063	0.016	NT	≤0.016
CBS 2226	≤0.008	0.016	NT	≤0.016
Caspofungin
VK065094T	0.5	0.5–1	NT	0.125–0.5
CBS 1913T	0.25–0.5	0.25	NT	0.125–0.5
CBS 2226	0.125–0.5	0.25	NT	0.125–0.25
Anidulafungin
VK065094T	0.125	0.25–0.5	NT	0.25–1
CBS 1913T	0.125–0.25	0.5	NT	0.25–0.5
CBS 2226	0.125–0.25	0.5	NT	0.25–0.5
Micafungin
VK065094T	0.5–1	1	NT	0.5–1
CBS 1913T	0.5–1	0.5	NT	0.5–1
CBS 2226	0.5	0.5	NT	0.5–1

^aResults were compared with the standard dilution testing (CLSI) and three commercial test systems, Etest, Vitek 2, and Micronaut. The CLSI, Etest, Vitek 2, and Micronaut tests were repeated six, two, four, and six times, respectively. NT, not tested.